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INTRODUCTION:  Pure  small  cell  prostate  cancer  (SCPC)  cases  are  very  rare.  Acute  zonal  occult  outer
retinopathy  (AZOOR)  has  been  described  as  a non-neoplastic  retinopathy.  We  report  the  ﬁrst  case of
pure  SCPC  preceded  by  AZOOR  in the  literature.
CASE  REPORT:  A 59  year  old gentleman  presented  with  an  obstructed  infected  urinary  system.  He had
a diagnosis  of  AZOOR  6 months  ago that  was investigated  with  full  body  imaging  without  any  suspi-
cious  ﬁndings.  However,  the most  recent  CT ﬁndings  demonstrated  extensive  disease  dissemination.  The
patient underwent  rigid  cystoscopy  and  resection  that  conﬁrmed  a diagnosis  of  pure  SCPC.
DISCUSSION:  AZOOR  is  a clinical  syndrome  of  photopsia  and  rapid  zonal  ﬁeld  loss.  The  exact  aetiology
remains  unknown  and  its association  with  malignancy  remains  contentious.  Paraneoplastic  manifesta-
tions  of  unexplained  visual  loss in  SCPC  are  rare  with only  2 cases  reported  in  the literature.  There  are no
cases  demonstrating  an  association  between  AZOOR  and  SCPC.
CONCLUSION:  Pure  SCPC  is  an  aggressive  malignancy  with  most  cases  presenting  with  extensive  disease
dissemination  on diagnosis.  Early  detection  has a role  in  improving  prognosis  but  is  challenging.  Further
research  is  required  to establish  a standard  treatment  protocol.
© 2016  The  Author(s).  Published  by  Elsevier  Ltd  on behalf  of IJS  Publishing  Group  Ltd.  This  is  an  open
access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Cancer of the prostate is usually acinar adenocarcinoma. Small
ell prostate cancers (SCPC) when they occur often present with
oexisting prostate adenocarcinoma. Pure SCPC cases are very
are. Paraneoplastic syndromes are frequently observed but visual
mpairment is unusual. Furthermore, acute zonal occult outer
etinopathy (AZOOR) has been described as a non-neoplastic
etinopathy. We  report the ﬁrst case of pure small cell carcinoma
f the prostate preceded by AZOOR in the literature.
. Case report
A previously ﬁt and healthy 59 year old Caucasian male pre-
ented to the emergency department with 1 day history of anuria,
n a background of 2 weeks gradual diminishing urine output. His
loods showed acute kidney injury with elevated inﬂammatory
arkers, consistent with an obstructed infected urinary system.
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reativecommons.org/licenses/by-nc-nd/4.0/).A non-contrast Computed Tomography (CT) performed showed
bilateral hydronephrosis, multiple diffuse enlarged pelvic and
abdominal lymph nodes and a mixture of osteoblastic/osteolytic
bone lesions throughout the spine (Fig. 1). His immediate manage-
ment involved bilateral nephrostomies and intravenous antibiotics.
Further bedside investigations included a digital rectal exam (DRE)
that was not suspicious for malignancy and a low age speciﬁc
prostate speciﬁc antigen (PSA) of 2.4.
This gentleman had no history of any genitourinary tract symp-
toms. His only past medical history was a recent diagnosis of AZOOR
by the ophthalmologist 6 months ago and he was  on prednisolone
4 mg  once daily. Due to the possible association between AZOOR
and malignancy, the ophthalmology team had previously requested
a Magnetic Resonance Imaging (MRI) head and a full body CT. Those
scans had returned without any suspicious ﬁndings. However, the
most recent CT ﬁndings demonstrated extensive disease dissemi-
nation.
On day 3 post admission, a rigid cystoscopy demonstrated
an enlarged, highly vascular and friable median lobe of the
prostate that extended into the bladder. The cystoscopy ﬁnd-
ings were characteristic of obstructive uropathy. A transurethral
resection of the prostate was  performed, with chips sent for
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. CT scan images of the patient’s abdomen and pelvis. (A) Bilateral hydronephrosis. (B) Extensive disease dissemination with lymph node involvement.
Fig. 2. Haematoxylin and eosin stain demonstrating small cells inﬁltrating muscle. Characteristically, the cells have ﬁne granular chromatin and scant cytoplasm.
Fig. 3. Strong cytoplasmic staining for synaptophysin conﬁrming neuroendocrine cells.
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istopathological analysis. No abnormalities were noted in the
ladder. Additional investigations included a bone scan, contrast
T chest/abdomen/pelvis and a MRI  spine, all of which delineated
idespread metastasis of bone, liver and lymph nodes.
Histopathology specimens conﬁrmed a diagnosis of high grade
mall cell prostate carcinoma without any evidence of coexisting
rothelial carcinoma or prostatic adenocarcinoma (Figs. 2 and 3).
he case was discussed at the urology multidisciplinary team
MDT) meeting. Upon diagnosis, the oncology team commenced
hemotherapy complemented with radiotherapy to the spinal
esions.
. Discussion
AZOOR is a rare eye disease characterised by focal degeneration
f photoreceptors [1]. It is a clinical syndrome of photopsia and
apid zonal ﬁeld loss [2]. The exact aetiology remains unknown and
as been reported to be associated with various ocular and systemic
iseases [1]. However its association with malignancy remains con-
entious, and a review by Rahimy et al. described AZOOR as a
on-paraneoplastic retinopathy [3].
Carcinoma of the prostate can be divided into two groups:
cinar and non-acinar. Small cell carcinomas (also known as neu-
oendocrine tumours) are of the non-acinar subgroup. Overall
on-acinar tumours account for approximately 5–10% of prostate
eoplasms, with SCPC ranging between 0.3–1% of all prostatic
umours [4].
It is worth noting that half of all SCPC cases were pure small
ell but the remaining were mixed adenocarcinomas. In fact, up to
ne third of patients with SCPC had a prior diagnosis of prostate
denocarcinoma [5,6]. The majority of cases are diagnosed in their
ixth to seventh decade, with an age range of 24–90 [7]. Studies
ave shown that the incidence of metastasis on diagnosis to be as
igh as 60.5% and the median survival observed was  just 11 months
a range of 5–17.5 months) [8].
There are distinctive differences between SCPC and adeno-
arcinoma in terms of clinical presentation. The most frequent
ymptoms of SCPC are related to obstructive uropathy and disease
issemination [7]. Pure SCPC may  secrete little or no PSA, or have
 PSA not in proportion to tumour size. Another unique feature
s the presentation of paraneoplastic syndromes including: Cush-
ng’s syndrome, hypercalcaemia and syndrome of inappropriate
ntidiuretic hormone [9]. However, paraneoplastic manifestations
f unexplained visual loss are decidedly rare – only 2 cases found in
he literature [10,11]. Moreover there are no cases reported in the
iterature demonstrating an association between AZOOR and SCPC.
evertheless, due to the presentation of AZOOR and SCPC 6 months
part in a previously ﬁt and well gentleman with negative imaging
esults, it would be plausible to suggest AZOOR as a paraneoplastic
anifestation for SCPC.
Due to the rare nature of this condition, there is a lack of evi-
ence guiding treatment for SCPC. Treatment modalities including
urgery, chemotherapy and radiotherapy mainly depend on the
tage of disease. Chemotherapy (particularly cisplatin and etopo-
ide) is the mainstay of treatment [12,13], due to the aggressive
ature of the disease. Survival closely associates with response to
reatment.
Radical surgical resection in combination with other treat-
ent modalities may  have a role in increasing survival rate [14].
adiotherapy can also be used to control local disease or allevi-
te metastatic symptoms [15]. The role of hormonal therapy is not
ecommended in pure SCPC and remains controversial in mixed
istologies. It has also been associated with the development of
euroendocrine differentiation in other forms of prostate cancer
15,16].
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4. Conclusion
Pure SCPC is an aggressive malignancy with most cases pre-
senting with extensive disease dissemination on diagnosis. Early
detection has a role in improving prognosis but is challenging. Fur-
ther research is required to establish a standard treatment protocol.
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